RECOMBINANT GAMMA-INTERFERON AS ADJUVANT TO HEPATITIS-B VACCINE IN HEMODIALYSIS-PATIENTS

被引:73
作者
QUIROGA, JA
CASTILLO, I
PORRES, JC
CASADO, S
SAEZ, F
MARTINEZ, MG
GOMEZ, M
INGLADA, L
SANCHEZSICILIA, L
MORA, A
GALIANA, F
BARRIL, G
CARRENO, V
机构
[1] FDN JIMENEZ DIAZ,DEPT GASTROENTEROL,HEPATOL UNIT,AVDA REYES CATOLICOS 2,E-28040 MADRID,SPAIN
[2] FDN JIMENEZ DIAZ,DEPT NEPHROL,MADRID,SPAIN
[3] CIUDAD SANITARIA SEGURIDAD SOCIAL LA PAZ,DEPT NEPHROL,MADRID,SPAIN
[4] BOEHRINGER INGELHEIM KG,DEPT MED,W-6507 INGELHEIM,GERMANY
[5] HOSP PRINCESA,DEPT NEPHROL,MADRID,SPAIN
关键词
D O I
10.1002/hep.1840120407
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Patients undergoing long‐term hemodialysis are at high risk of acquiring hepatitis B yet tend to have poor rates of response to hepatitis B vaccine. The effect of recombinant human γ‐interferon (2 million units/m2) on the response to a recombinant hepatitis B vaccine was evaluated in a prospective, randomized controlled trial in 81 hemodialysis patients. A similar proportion of both groups of vaccinees ultimately developed antibody to HBsAg including 81% of the 41 recipients of vaccine alone (group I) and 89% of the 40 recipients of vaccine with γ‐interferon (group II). However, the antibody to HBsAg response occurred earlier in recipients of vaccine with γ‐interferon, so that at 4 mo 63% of group I and 88% of group II had antibody to HBsAg (p < 0.025). Furthermore, titers of antibody to HBsAg tended to be higher in the vaccinees given interferon; the final geometric mean titers were 232 IU/L in group I and 330 IU/L in group II (p = not significant). Retrospective testing for antibody to hepatitis C virus revealed that 21 (26%) hemodialysis patients were seropositive at entry into this trial, but the presence of antibody to hepatitis C virus did not appear to affect the response rate to the hepatitis B vaccine. These results suggest that the effects of γ‐interferon as an adjuvant in increasing the response rate to hepatitis B vaccination deserve further evaluation perhaps most appropriately in persons who have not responded to an initial course of vaccine. (HEPATOLOGY 1990;12:661–663). Copyright © 1990 American Association for the Study of Liver Diseases
引用
收藏
页码:661 / 663
页数:3
相关论文
共 14 条
  • [1] ANDRE FE, 1988, VIRAL HEPATITIS LIVE, P1025
  • [2] CARRENO V, 1985, CLIN NEPHROL, V24, P215
  • [3] CROSNIER J, 1981, LANCET, V1, P797
  • [4] ESTEBAN JI, 1989, LANCET, V2, P294
  • [5] INTERFERON AS AN ADJUVANT FOR HEPATITIS-B VACCINATION IN NON-RESPONDER AND LOW-RESPONDER POPULATIONS
    GROB, PJ
    JOLLERJEMELKA, HI
    BINSWANGER, U
    ZARUBA, K
    DESCOEUDRES, C
    FERNEX, M
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1984, 3 (03) : 195 - 198
  • [6] RESULTS OF IMMUNIZATION WITH A RECOMBINANT YEAST-DERIVED HEPATITIS-B VACCINE
    JILG, W
    DEINHARDT, F
    [J]. JOURNAL OF INFECTION, 1986, 13 : 47 - 51
  • [7] NEUTRALIZATION OF INTERFERON BY ANTIBODY - APPRAISALS OF METHODS OF DETERMINING AND EXPRESSING THE NEUTRALIZATION TITER
    KAWADE, Y
    WATANABE, Y
    [J]. JOURNAL OF INTERFERON RESEARCH, 1984, 4 (04): : 571 - 584
  • [8] AN ASSAY FOR CIRCULATING ANTIBODIES TO A MAJOR ETIOLOGIC VIRUS OF HUMAN NON-A, NON-B-HEPATITIS
    KUO, G
    CHOO, QL
    ALTER, HJ
    GITNICK, GL
    REDEKER, AG
    PURCELL, RH
    MIYAMURA, T
    DIENSTAG, JL
    ALTER, MJ
    STEVENS, CE
    TEGTMEIER, GE
    BONINO, F
    COLOMBO, M
    LEE, WS
    KUO, C
    BERGER, K
    SHUSTER, JR
    OVERBY, LR
    BRADLEY, DW
    HOUGHTON, M
    [J]. SCIENCE, 1989, 244 (4902) : 362 - 364
  • [9] BIOCHEMISTRY OF INTERFERONS AND THEIR ACTIONS
    LENGYEL, P
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1982, 51 : 251 - 282
  • [10] MEUER SC, 1989, LANCET, V1, P15